Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMP
CUSIPN/A
Phone858-997-2400
Debt
Debt-to-Equity Ratio0.07
Current Ratio1.88
Quick Ratio1.57
Price-To-Earnings
Trailing P/E Ratio-4.47
Forward P/E Ratio-5.83
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.07 million
Price / Sales10.28
Cash FlowN/A
Price / CashN/A
Book Value$1.18 per share
Price / Book3.41
Profitability
EPS (Most Recent Fiscal Year)($0.90)
Net Income$-25,530,000.00
Net Margins-207.24%
Return on Equity-71.68%
Return on Assets-56.06%
Miscellaneous
Employees126
Outstanding Shares33,390,000
Market Cap$134.39
Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions
What is Adamis Pharmaceuticals' stock symbol?
Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."
How were Adamis Pharmaceuticals' earnings last quarter?
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) issued its earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.06. The specialty pharmaceutical company earned $3.18 million during the quarter, compared to analyst estimates of $3.34 million. Adamis Pharmaceuticals had a negative net margin of 207.24% and a negative return on equity of 71.68%. View Adamis Pharmaceuticals' Earnings History.
When is Adamis Pharmaceuticals' next earnings date?
What price target have analysts set for ADMP?
4 analysts have issued twelve-month price objectives for Adamis Pharmaceuticals' stock. Their forecasts range from $7.00 to $13.00. On average, they anticipate Adamis Pharmaceuticals' share price to reach $9.3750 in the next year. This suggests a possible upside of 132.9% from the stock's current price. View Analyst Ratings for Adamis Pharmaceuticals.
What is the consensus analysts' recommendation for Adamis Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Adamis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (7/4/2018)
- 2. Maxim Group analysts commented, "Adamis reported 1Q18 with revenue of $3.2M from the compounding business, up 11.9% sequentially. The company ended the period with a net loss of $7.6M and $10.1M in cash on the balance sheet. Growing revenue in the compounding business should continue to partially offset cash burn and we expect that a partnership for Symjepi to come with an upfront payment that could extend the runway. Partnering discussions are advancing. We have removed the risk cut in our Symjepi model (prior 30%) and made some other minor model, increasing PT to $10, from $5.." (5/11/2018)
Who are some of Adamis Pharmaceuticals' key competitors?
Some companies that are related to Adamis Pharmaceuticals include TIGENIX/S (TIG), ArQule (ARQL), Keryx Biopharmaceuticals (KERX), Depomed (DEPO), Lannett (LCI), Cytokinetics (CYTK), Aurinia Pharmaceuticals (AUPH), Stemline Therapeutics (STML), Verastem (VSTM), Dermira (DERM), Unum Therapeutics (UMRX), Zymeworks (ZYME), Verrica Pharmaceuticals (VRCA), Synergy Pharmaceuticals (SGYP) and Rigel Pharmaceuticals (RIGL).
Who are Adamis Pharmaceuticals' key executives?
Adamis Pharmaceuticals' management team includes the folowing people:
- Mr. Richard C. Williams, Chairman and Consultant (Age 74)
- Dr. Dennis J. Carlo Ph.D., Chief Exec. Officer, Pres and Director (Age 75)
- Mr. Robert O. Hopkins, Chief Financial Officer, VP of Fin. and Sec. (Age 58)
- Mr. David J. Marguglio, Chief Bus. Officer, Sr. VP and Director (Age 48)
- Mr. Robert B. Rothermel, Consultant and Director (Age 74)
Has Adamis Pharmaceuticals been receiving favorable news coverage?
Press coverage about ADMP stock has been trending positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of 0.28 on Accern's scale. They also gave press coverage about the specialty pharmaceutical company an impact score of 45.74 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Adamis Pharmaceuticals?
Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamis Pharmaceuticals' stock price today?
One share of ADMP stock can currently be purchased for approximately $4.0250.
How big of a company is Adamis Pharmaceuticals?
Adamis Pharmaceuticals has a market capitalization of $134.39 million and generates $13.07 million in revenue each year. The specialty pharmaceutical company earns $-25,530,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Adamis Pharmaceuticals employs 126 workers across the globe.
How can I contact Adamis Pharmaceuticals?
Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]
MarketBeat Community Rating for Adamis Pharmaceuticals (NASDAQ ADMP)
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
